Stock Investing
Be ready for liftoff for Supernus Pharmaceuticals Inc. (SUPN)
Qelbree, a drug developed by Supernus Pharmaceuticals, Inc. (SUPN), recently received FDA approval. Consequently, SUPN shares traded at 30.11 USD on April 5th for a gain of 12.7%. Qelbree is specifically approved to treat attention deficit hyperactivity disorder in patients between the ages of 6
